Physical
Pharmacological
Endovascular
Induced Hypertension
- Improves CBF (possibly more in areas of vasospasm) with associated clinical improvement
- Noradrenaline safe and usually first line - no risk of increased vasospasm
- No evidence of new rupture risk
- No clear BP target or duration:
- Evidence limited
- Used on clinical grounds assessing response to therapy or reductions
- Limited value when infarct established
Euvolaemia
- Optimises cerebral blood flow
- Cardiac output monitoring may be useful to guide fluid therapy
- Hypervolaemia associated with increased complications
Nimodipine
- Standard dose is 60mg 4 hourly
- May cause hypotension - if so reduce dose to 30mg 2 hourly
- Given for 21 days
- Not used for traumatic SAH
Magnesium
- No proven benefit
- Maintenance within normal levels usually advocated
Angiography & stents / intraarterial vasodilators
- Lower risk of DCI
- Higher risk of vessel rupture
- No change in all cause mortality - role unclear
- Consider in those refractory to medical therapy